TITAN PHARMACEUTICALS INC: M&A transaction — Titan Pharmaceuticals completes merger with Black Titan; shares to cease trading on Nasdaq

TITAN PHARMACEUTICALS INC

On Oct 1, 2025, Titan merged with Black Titan subsidiary; TTNP shares convert to PubCo ordinary shares.
TalenTec shareholders contributed shares for PubCo shares; PubCo shares to start trading Oct 2 on Nasdaq.
All TTNP directors and officers resigned; Chay Weei Jye appointed as sole director and acting secretary.

item 2.01 item 3.03 item 5.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

TITAN PHARMACEUTICALS INC underwent a change of control involving Black Titan Corporation (closed 2025-10-01).

Action: change of control
Counterparty: Black Titan Corporation
Closing: 2025-10-01

Exact text from the filing

Upon the terms and subject to the conditions of the Merger Agreement, on October 1, 2025, at the effective time of the Merger (the “ Effective Time ”), Merger Sub merged with and into Parent (the “ Merger ”), with Parent continuing as the surviving corporation under the same name as a direct wholly owned subsidiary of Black Titan.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001829126-25-007823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.